Mineralys Therapeutics Inc (MLYS) Actualités

Form 8-K - Current report

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to...

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage...

Form 8-K - Current report

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – –...

Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage...

Form 8-K - Current report

Form 8-K - Current report